Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
RATIONALE: The N-methyl-D-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal models of depression. OBJECTIVE: We compared the rapid and sustained antidepressant effects of R-ketamine and rapastinel in the social defeat stress model. RESULTS: In the tail suspension and forced swimming tests, R-ketamine (10 mg/kg, intraperitoneal (i.p.)) or rapastinel (10 mg/kg, i.p.) significantly attenuated the increased immobility time in the susceptible mice, compared with the vehicle-treated group. In the sucrose preference test, both compounds significantly enhanced the reduced preference in susceptible mice 2, 4, or 7 days after a single injection. All mice were sacrificed 8 days after a single injection. Western blot analyses showed that R-ketamine, but not rapastinel, significantly attenuated the reduced brain-derived neurotrophic factor (BDNF)-TrkB signaling, postsynaptic density protein 95 (PSD-95), and GluA1 (a subtype of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor) in the prefrontal cortex, dentate gyrus, and CA3 of the hippocampus in the susceptible mice. In contrast, both compounds had no effect against the increased BDNF-TrkB signaling, PSD-95, and GluA1 seen in the nucleus accumbens of susceptible mice. Moreover, sustained antidepressant effect of R-ketamine (3 mg/kg, intravenous (i.v.)), but not rapastinel (3 mg/kg, i.v.), was detected 7 days after a single dose. CONCLUSIONS: These results highlight R-ketamine as a longer lasting antidepressant compared with rapastinel in social defeat stress model. It is likely that synaptogenesis including BDNF-TrkB signaling in the prefrontal cortex (PFC) and hippocampus may be required for the mechanisms promoting this sustained antidepressant effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical evidence suggests that rapastinel may enhance dendritic complexity and long-term potentiation via bidirectional modulation of NMDA signal transduction [161,162,163].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [163]
Experimental — accuracy not yet measuredIn the citing paper
“Another finding challenging the NMDAR inhibition hypothesis of ketamine’s antidepressant mechanism of action is the fact that partial agonists at the NMDAR glycineB binding site, including GLYX-13 (i.e., rapastinel) and D-cycloserine manifest antidepressant effects in clinical trials 104, 105 and in animal tests 106–109, without sharing ketamine’s NMDAR inhibition-mediated side effects 109.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu121 · Cited by 103 · cited 16×
“Effects of i.p. administration of R-ketamine and rapastinel in the social defeat stress model Ketamine produces rapid and long-lasting antidepressant effects in the chronic mild stress model and social defeat stress model (Li et al. 2010; Ma et al. 2013; Yang et al. 2015b; Zhang et al. 2015b).”
BackgroundMethodResultInfluentialSelf-citationRetractedMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 2×
“A single sub-anesthet ic dose (0.5 mg/kg) of ketamine produces a rapid and robust antidepressant response in two-thirds of patients with treatment-resistant depression, which can last for over a week (Aan Het Rot et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Zarate et al. 2006; 2012).”
BackgroundInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 2×
“A single sub-anesthet ic dose (0.5 mg/kg) of ketamine produces a rapid and robust antidepressant response in two-thirds of patients with treatment-resistant depression, which can last for over a week (Aan Het Rot et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Zarate et al. 2006; 2012).”
BackgroundInfluentialmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“Ketamine produces rapid and long-lasting antidepressant effects in the chronic mild stress model and social defeat stress model (Li et al. 2010; Ma et al. 2013; Yang et al. 2015b; Zhang et al. 2015b).”
BackgroundEssential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 1×
“The social defeat procedure was performed as previously reported (Berton et al. 2006; Golden et al. 2011; Ren et al. 2016; Yang et al. 2015b; Zhang et al. 2015b).”
MethodThe mesolimbic dopamine reward circuit in depression
Nestler, E. J., & Carlezon, W. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.018 · Cited by 2,059 · cited 1×
“N.S. not significant, Con control, Veh vehicle, R-Ket R-ketamine, Rap rapastinel BDNF activity in the NAc produced antidepressant-like effects (Nestler and Carlezon 2006).”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 4×
“In addition, we performedWestern blot analysis of brain-derived neurotrophic factor (BDNF)TrkB pathway, postsynaptic density protein 95 (PSD-95), and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (GluA1), both of which are required for synaptic plasticity in selected brain regions, since BDN…”
BackgroundMethodInfluentialSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 3×
“In addition, we performedWestern blot analysis of brain-derived neurotrophic factor (BDNF)TrkB pathway, postsynaptic density protein 95 (PSD-95), and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (GluA1), both of which are required for synaptic plasticity in selected brain regions, since BDN…”
BackgroundMethodA standardized protocol for repeated social defeat stress in mice
Golden, S. A., Covington, H. E., Berton, O., & Russo, S. J. (2011) · Nature Protocols · doi:10.1038/nprot.2011.361 · Cited by 1,581 · cited 1×
“The social defeat procedure was performed as previously reported (Berton et al. 2006; Golden et al. 2011; Ren et al. 2016; Yang et al. 2015b; Zhang et al. 2015b).”
MethodDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963 · cited 3×
“A single sub-anesthet ic dose (0.5 mg/kg) of ketamine produces a rapid and robust antidepressant response in two-thirds of patients with treatment-resistant depression, which can last for over a week (Aan Het Rot et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Zarate et al. 2006; 2012).”
BackgroundResultInfluentialZarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605 · cited 15×
“Effects of i.p. administration of R-ketamine and rapastinel in the social defeat stress model Ketamine produces rapid and long-lasting antidepressant effects in the chronic mild stress model and social defeat stress model (Li et al. 2010; Ma et al. 2013; Yang et al. 2015b; Zhang et al. 2015b).”
BackgroundMethodResultInfluentialSelf-citationDomino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466 · cited 2×
“Synaptogenesis”
BackgroundKetamine for Depression: Where Do We Go from Here?
aan het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.003 · Cited by 418 · cited 3×
“A single sub-anesthet ic dose (0.5 mg/kg) of ketamine produces a rapid and robust antidepressant response in two-thirds of patients with treatment-resistant depression, which can last for over a week (Aan Het Rot et al. 2012; Berman et al. 2000; Diazgranados et al. 2010; Zarate et al. 2006; 2012).”
BackgroundInfluentialRapid-acting glutamatergic antidepressants: the path to ketamine and beyond
Krystal, J. H., Sanacora, G., & Duman, R. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.026 · Cited by 406 · cited 2×
“Synaptogenesis”
BackgroundEmerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381 · cited 1×
“…of the most attractive antidepressants for treatment-resistant depression (Aan Het Rot et al. 2012; Chaki and Fukumoto, 2015; Krystal et al. 2013; Hashimoto 2009; Hashimoto et al. 2013; Lodge and Mercier, 2015; Sanacora and Schatzberg 2015; Yang and * Kenji Hashimoto…”
BackgroundSelf-citationBDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368 · cited 4×
“In addition, we performedWestern blot analysis of brain-derived neurotrophic factor (BDNF)TrkB pathway, postsynaptic density protein 95 (PSD-95), and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (GluA1), both of which are required for synaptic plasticity in selected brain regions, since BDN…”
BackgroundMethodInfluentialR (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357 · cited 4×
“The doses of R-ketamine (10 mg/kg) and rapastinel (10 mg/kg) were selected as reported previously (Lu et al. 2014; Yang et al. 2015b, 2016; Zhang et al. 2014).”
BackgroundMethodInfluentialSelf-citationZhang, J.-C., Wu, J., Fujita, Y., Yao, W., Ren, Q., Yang, C., Li, S.-X., Shirayama, Y., & Hashimoto, K. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu077 · Cited by 289 · cited 12×
“We recently reported that TrkB agonist 7,8-DHF and TrkB antagonist ANA-12 showed antidepressant activity on inflammation (or social defeat stress)-induced depressive behavior, by normalizing altered dendritic spines in the PFC and hippocampus and NAc, respectively (Zhang et al. 2015a; 2015b).”
BackgroundMethodResultInfluentialSelf-citationBurgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284 · cited 3×
“The dose of rapastinel (3 mg/kg) was selected as reported previously (Burgdorf et al. 2013).”
BackgroundMethodGlutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Hashimoto, K., Malchow, B., Falkai, P., & Schmitt, A. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0399-y · Cited by 219 · cited 1×
“…antidepressants for treatment-resistant depression (Aan Het Rot et al. 2012; Chaki and Fukumoto, 2015; Krystal et al. 2013; Hashimoto 2009; Hashimoto et al. 2013; Lodge and Mercier, 2015; Sanacora and Schatzberg 2015; Yang and * Kenji Hashimoto hashimoto@faculty.chiba-u.jp 1 Division of…”
BackgroundSelf-citationPRESKORN, S., MACALUSO, M., MEHRA, D. V., ZAMMIT, G., MOSKAL, J. R., & BURCH, R. M. (2015) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000462606.17725.93 · Cited by 193 · cited 1×
“The BDNF-TrkB pathway in the NAc plays a role in the depression phenotype (Nestler and Carlezon 2006; Ren et al, 2015; Yang et al. 2015a; Zhang et al. 2015a; 2015b).”
BackgroundKetamine and phencyclidine: the good, the bad and the unexpected
Lodge, D., & Mercier, M. S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13222 · Cited by 184 · cited 2×
“Synaptogenesis”
BackgroundZhang, J.-C., Yao, W., Dong, C., Yang, C., Ren, Q., Ma, M., Han, M., & Hashimoto, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4062-3 · Cited by 183 · cited 12×
“We recently reported that TrkB agonist 7,8-DHF and TrkB antagonist ANA-12 showed antidepressant activity on inflammation (or social defeat stress)-induced depressive behavior, by normalizing altered dendritic spines in the PFC and hippocampus and NAc, respectively (Zhang et al. 2015a; 2015b).”
BackgroundMethodResultInfluentialSelf-citationRen, Q., Ma, M., Ishima, T., Morisseau, C., Yang, J., Wagner, K. M., Zhang, J.-C., Yang, C., Yao, W., Dong, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601532113 · Cited by 162 · cited 5×
“4a), consistent with previous data from the social defeat stress model of depression (Ren et al. 2016; Yang et al. 2015b; Zhang et al. 2015b).”
MethodResultInfluentialSelf-citationSanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Antidepressant actions of ketamine: from molecular mechanisms to clinical practice
Monteggia, L. M., & Zarate, C. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2014.12.004 · Cited by 149 · cited 1×
“Synaptogenesis”
Shirayama, Y., Yang, C., Zhang, J.-C., Ren, Q., Yao, W., & Hashimoto, K. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.09.002 · Cited by 137
Self-citationInflammatory Biomarkers as Differential Predictors of Antidepressant Response
Hashimoto, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16047796 · Cited by 137 · cited 1×
“Therefore, the development of novel drugs capable of inducing rapid and robust antidepressant responses in treatment-resistant depressed patients is required (Chaki and Fukumoto, 2015; Hashimoto 2015; Monteggia and Zarate 2015).”
BackgroundSelf-citationMoskal, J. R., Burch, R., Burgdorf, J. S., Kroes, R. A., Stanton, P. K., Disterhoft, J. F., & Leander, J. D. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.852536 · Cited by 131 · cited 1×
“Rapastinel (formerly GLYX-13), a partial agonist at glycine site of the NMDA receptor, shows antidepressant-like effects without ketamine-like side effects in animal models (Burgdorf et al. 2013; Moskal et al. 2014; 2016).”
BackgroundMa, X.-C., Dang, Y.-H., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C.-G., & Hashimoto, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056053 · Cited by 114 · cited 2×
“Ketamine produces rapid and long-lasting antidepressant effects in the chronic mild stress model and social defeat stress model (Li et al. 2010; Ma et al. 2013; Yang et al. 2015b; Zhang et al. 2015b).”
BackgroundSelf-citationOhgi, Y., Futamura, T., & Hashimoto, K. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150330143008 · Cited by 107 · cited 3×
“In addition, we performedWestern blot analysis of brain-derived neurotrophic factor (BDNF)TrkB pathway, postsynaptic density protein 95 (PSD-95), and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (GluA1), both of which are required for synaptic plasticity in selected brain regions, since BDN…”
BackgroundMethodSelf-citationRen, Q., Ma, M., Yang, C., Zhang, J.-C., Yao, W., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.157 · Cited by 100 · cited 3×
“The BDNF-TrkB pathway in the NAc plays a role in the depression phenotype (Nestler and Carlezon 2006; Ren et al, 2015; Yang et al. 2015a; Zhang et al. 2015a; 2015b).”
BackgroundMethodInfluentialSelf-citationThe Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant
Moskal, J. R., Burgdorf, J. S., Stanton, P. K., Kroes, R. A., Disterhoft, J. F., Burch, R. M., & Khan, M. A. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160321122703 · Cited by 92
Yang, C., Han, M., Zhang, J.-C., Ren, Q., & Hashimoto, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.03.034 · Cited by 91
Self-citationLu, Y., Wang, C., Xue, Z., Li, C., Zhang, J., Zhao, X., Liu, A., Wang, Q., & Zhou, W. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu110 · Cited by 75 · cited 1×
“The doses of R-ketamine (10 mg/kg) and rapastinel (10 mg/kg) were selected as reported previously (Lu et al. 2014; Yang et al. 2015b, 2016; Zhang et al. 2014).”
MethodSelf-citationChronopharmacological studies of ketamine in normal and NMDA Ε1 receptor knockout mice †
Sato, Y., Kobayashi, E., Hakamata, Y., Kobahashi, M., Wainai, T., Murayama, T., Mishina, M., & Seo, N. (2004) · British Journal of Anaesthesia · doi:10.1093/bja/aeh144 · Cited by 64 · cited 1×
“The half-life of ketamine in mouse plasma is approximately 30 min (Sato et al. 2004), suggesting a possible rapid clearance of R-ketamine from the body.”
BackgroundHashimoto, K. (2016) · Psychological Medicine · doi:10.1017/s0033291716000969 · Cited by 54 · cited 1×
“…Rketamine appears to be a potent, long-lasting, and safe antidepressant, relative to esketamine, since R-ketamine may appear to be free of side effects such as psychosis and abuse liability (Hashimoto 2014, 2016a, 2016b; Yang and Hashimoto 2014; Yang et al. 2015b, 2016; Zhang et al. 2014).”
BackgroundSelf-citationRapid antidepressant effects and abuse liability of ketamine
Yang, C., & Hashimoto, K. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3543-0 · Cited by 46 · cited 1×
“…Rketamine appears to be a potent, long-lasting, and safe antidepressant, relative to esketamine, since R-ketamine may appear to be free of side effects such as psychosis and abuse liability (Hashimoto 2014, 2016a, 2016b; Yang and Hashimoto 2014; Yang et al. 2015b, 2016; Zhang et al. 2014).”
BackgroundSelf-citationHashimoto, K. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.1.72 · Cited by 42 · cited 5×
“…2015; Yang and * Kenji Hashimoto hashimoto@faculty.chiba-u.jp 1 Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba 260-8670, Japan 2 Department of Neurosurgery, Renmin Hospital ofWuhan University, Wuhan, Hubei, People’s Republic of China Hashimoto 2014).”
BackgroundInfluentialSelf-citationDetrimental Side Effects of Repeated Ketamine Infusions in the Brain
Hashimoto, K. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16040411 · Cited by 35 · cited 1×
“…Rketamine appears to be a potent, long-lasting, and safe antidepressant, relative to esketamine, since R-ketamine may appear to be free of side effects such as psychosis and abuse liability (Hashimoto 2014, 2016a, 2016b; Yang and Hashimoto 2014; Yang et al. 2015b, 2016; Zhang et al. 2014).”
BackgroundSelf-citationPotential of Glutamate-Based Drug Discovery for Next Generation Antidepressants
Chaki, S., & Fukumoto, K. (2015) · Pharmaceuticals · doi:10.3390/ph8030590 · Cited by 35 · cited 2×
“…(NMDA) receptor antagonist ketamine is one of the most attractive antidepressants for treatment-resistant depression (Aan Het Rot et al. 2012; Chaki and Fukumoto, 2015; Krystal et al. 2013; Hashimoto 2009; Hashimoto et al. 2013; Lodge and Mercier, 2015; Sanacora and Schatzberg 2015; Yang…”
Background
Cited by
Major depressive disorder: hypothesis, mechanism, prevention and treatment
Cui, L., Li, S., Wang, S., Wu, X., Liu, Y., Yu, W., Wang, Y., Tang, Y., Xia, M., & Li, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01738-y · Cited by 1,244
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127
Animal models of major depression: drawbacks and challenges
Planchez, B., Surget, A., & Belzung, C. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02084-y · Cited by 480
Protein lactylation induced by neural excitation
Hagihara, H., Shoji, H., Otabi, H., Toyoda, A., Katoh, K., Namihira, M., & Miyakawa, T. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109820 · Cited by 349
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“Furthermore, (R)-ketamine elicited longer-lasting antidepressant actions than rapastinel in a CSDS model.(155) Intravenous administration of rapastinel (5 or 10 mg/kg) showed antidepressant actions in depressed patients who did not respond to another antidepressant.”
BackgroundSelf-citation
Metadata
- Authors
- Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K.
- Affiliations
- Chiba University (JP)
- Corresponding author
- Hashimoto, Kenji
- Venue
- Psychopharmacology
- Published
- 2016-08-04
- Volume
- 233
- Issue
- 19-20
- Pages
- 3647-3657
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- PMC
- PMC5021744
- OpenAlex
- W2499491810
- Cited by
- 91
- References
- 44
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 11 · 2020: 7 · 2019: 14 · 2018: 14 · 2017: 19 · 2016: 3
- FWCI
- 13.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- KAKENHI, Japan (24116006)
- The Strategic Research Program for Brain Sciences from Japan Agency for Medical Research and development, AMED
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- (R)-ketamine, antidepressant effects, social defeat stress, NMDA receptor antagonists, BDNF/TrkB signaling, PSD-95, GluR1, AMPA receptors, synaptogenesis, prefrontal cortex, hippocampus, nucleus accumbens, rapid-acting antidepressants, depression
- MeSH terms
- Disks Large Homolog 4 Protein, Animals, Antidepressive Agents, Brain, Depression, Disease Models, Animal, Hippocampus, Ketamine, Male, Nucleus Accumbens, Oligopeptides, Stress, Psychological, Swimming, Prefrontal Cortex, Receptors, AMPA, Excitatory Amino Acid Antagonists, Dentate Gyrus, Brain-Derived Neurotrophic Factor, Hindlimb Suspension, Receptor, trkB, Mice, CA3 Region, Hippocampal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.